PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media - STEMCELL Technologies, Inc. announced this week the launch of StemSpan™ ACF - Stemcell.com
STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2012/07/17 - STEMCELL Technologies, Inc. announced this week the launch of StemSpan™ ACF - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies Inc. announced this week the launch of StemSpan™ ACF, a new animal component- free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. While serum-free media is well established, this is the first complete medium available for the culture and expansion of hematopoietic stem cells that is free of animal and human proteins and only contains recombinant and synthetic components.

StemSpan™ ACF presents a huge leap forward in the field of hematopoietic cell culture as it allows researchers to study hematopoiesis and cell therapy development without concerns of transmission of adventitious agents from plasma derived components, or lack of consistency between different lots of human or bovine proteins in other complete media formulations.

“StemSpan™ ACF supports equivalent total nuclear cell and CD34+ cell expansion as the existing highest performance serum-free medium on the market,” said Dr. Bert Wognum, the senior scientist responsible for hematopoietic stem cell expansion medium development at STEMCELL Technologies. “It also supports monocyte to dendritic cell differentiation and might be used by researchers to develop and optimize their own culture systems to generate large numbers of other mature blood cells.”

“We are delighted to build on our track record for providing high performance hematopoietic serum-free media to scientists, by introducing products like StemSpan™ ACF that take the field to a new and highly awaited level,” said Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “We are excited to give scientists products that take their work to the next phase and remove the difficulties associated with plasma-derived components in other serum-free media.”

By adding StemSpan™ ACF to its portfolio, STEMCELL Technologies (Stemcell.com) continues to support the movement of hematopoietic stem cell expansion research toward cell therapy development and clinical relevance. The high-quality StemSpan products include StemSpan™ SFEM, StemSpan H3000, and StemSpan™ ACF for ex vivo expansion of hematopoietic progenitor cells. For more information about StemSpan™ ACF and for technical resources on hematopoietic stem cell expansion, please visit our product page.

Contact
Isis Carter, PhD, Product Manager
STEMCELL Technologies Inc. P: 604-668-0875

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Stemcell |
Publisher Contact: Press Office - Stemcell.com 
604-877-0713
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)